Exemestan zlepšuje výsledky adjuvantní léčby hormon-dependentního karcinomu mléčné žlázy u postmenopauzálních žen
- Kuwait Cancer Control Center, Medical Oncology
Podle interview s hlavním řešitelem studie, Dr. R. C. Coombsem - Multicentrická randomizovaná studie IES (Intergroup Exemestane Study) prokázala, že sekvenční podání selektivního inhibitoru aromatázy Aromasinu (exemestan, Pfizer) po tamoxifenu u časného hormon-dependentního karcinomu prsu u postmenopauzálních žen zvyšuje naději na vyléčení. Definitivní výsledky byly prezentovány na ASCO Annual Meeting 2006...
Published: May 5, 2007 Show citation
References
- Bertelli G et al. Intergroup AROMASIN Study: Results of the Endometrial Sub-Protocol, Presented at SABCS 2004, USA.
- Coombes RC. A Randomized Trial of AROMASIN after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. N Engl J Med. March 11, 2004. Vol. 350 No. 11.
Go to original source... 
Go to PubMed... - Coombes RC. First mature survival analysis of the Intergroup Exemestane Study: a randomised trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen. Abstract LBA527, presented at ASCO 2006 OR [Details of Clinical Study Report to be inserted pending availability.].
- Coleman RE et al. Intergroup Exemestane Study (IES): 1 years results of the bone sub-protocol. Presented at SABCS 2004, USA.
- Coleman RE et al. Skeletal effects of AROMASIN in the Intergroup AROMASIN Study (IES) two year bone mineral density and bone biomarker data. Presented on December 10 2005, SABCS, USA.
- Fallowfield LJ et al. Quality of Life in the Intergroup AROMASIN Study (IES) - a Randomized Trial of AROMASIN versus Continued Tamoxifen after 2-3 years of Tamoxifen in Postmenopausal Women with Primary Breast Cancer. Journal of Clinical Oncology. Vol 24, No 6, Feb 20, 2006. Go to original source... Go to PubMed...
- Lundkvist et al. Cost-effectiveness of exemestane versus tamoxifen ad adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Poster 358 presented at EBCC 2006. Go to original source...
- Risebrough NA et al. Economic evaluation of switching to AROMASIN at 2.5 years versus continuing tamoxifen as adjuvant therapy in early breast cancer: A Canadian perspective. Poster 2060 presented at SABCS 2005.
- Thompson D et al. Cost-Effectiveness of Switching to AROMASIN Following Two-to-Three Years of Therapy with Tamoxifen in Postmenopausal Women with Primary Breast Cancer, Poster 5037 presented at SABCS 2005.
- Wordsworth et al. Exemestane in adjuvant treatment of early-stage breast cancer in postmenopausal women: results of a UK cost-effectiveness model, Poster 354 presented at EBCC 2006.